Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide.

Trial Profile

Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan; Prednisone; Thalidomide
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results of validation of the SKY92 gene expression classifier and rISS in patients from this trial presented at the 22nd Congress of the European Haematology Association.
    • 22 Jan 2016 Results published in the Blood
    • 20 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by Netherlands Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top